Ovid Therapeutics Inc.
OVIDNASDAQHealthcare● Active
$2.36
$-0.04(-1.67%)
Market Cap$311247347
P/E Ratio—
52W High$3.105
52W Low$0.272
Ovid Therapeutics Inc. (OVID) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
OVID · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.12
Est. -$0.12 · +0.0%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
✓ 2-Quarter EPS Beat Streak
OVID reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.12 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 12, 2026 | -$0.12 | -$0.12 | +0.0% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 18, 2026 | -$0.10 | $0.06 | +160.0% | $0.00B | $0.00B | +817.6% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.15 | -$0.17 | -13.3% | $0.00B | $0.00B | +110.9% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.16 | -$0.06 | +62.5% | $0.01B | $0.00B | +10126.6% |
| — Q2 FY2025 | May 13, 2025 | -$0.14 | -$0.14 | +0.0% | $0.00B | $0.00B | +205.9% |
| ▲ Q1 FY2025 | Mar 11, 2025 | -$0.16 | -$0.13 | +18.8% | $0.00B | $0.00B | -24.0% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.19 | -$0.20 | -5.3% | $0.00B | $0.00B | -7.7% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.12
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026
EPS Actual
-$0.12
EPS Est.
-$0.12
EPS Surpr.
+0.0%
Revenue
—
Q1 FY2026
Mar 18, 2026Beat
EPS Actual
$0.06
EPS Est.
-$0.10
EPS Surpr.
+160.0%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.17
EPS Est.
-$0.15
EPS Surpr.
-13.3%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.16
EPS Surpr.
+62.5%
Revenue
$0.01B
Q2 FY2025
May 13, 2025
EPS Actual
-$0.14
EPS Est.
-$0.14
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 11, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.16
EPS Surpr.
+18.8%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.20
EPS Est.
-$0.19
EPS Surpr.
-5.3%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.14 | $-0.09 | $-0.04 | 5 |
| Q3 FY2028 | $-0.15 | $-0.09 | $-0.04 | 5 |
| Q2 FY2028 | $-0.14 | $-0.09 | $-0.04 | 6 |
| Q1 FY2028 | $-0.14 | $-0.09 | $-0.04 | 3 |
| Q4 FY2027 | $-0.18 | $-0.12 | $-0.05 | 2 |
| Q3 FY2027 | $-0.17 | $-0.11 | $-0.05 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +0.0% | $2.79 | $2.87 | +2.87% |
| ▲ Q1 FY2026 | Mar 18, 2026 | +160.0% | $2.01 | $2.30 | +14.43% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -13.3% | $1.35 | $1.32 | -2.22% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +62.5% | $0.55 | $0.86 | +56.86% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $0.30 | $0.29 | -5.30% |
| ▲ Q1 FY2025 | Mar 11, 2025 | +18.8% | $0.49 | $0.49 | +0.08% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -5.3% | $1.36 | $1.24 | -8.82% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +154.6% | $0.84 | $0.88 | +3.96% |
Q2 FY2026+2.87%
Report Date
May 12, 2026
EPS Beat/Miss
+0.0%
Price Before
$2.79
Price After
$2.87
Q1 FY2026+14.43%
Report Date
Mar 18, 2026
EPS Beat/Miss
+160.0%
Price Before
$2.01
Price After
$2.30
Q4 FY2025-2.22%
Report Date
Nov 12, 2025
EPS Beat/Miss
-13.3%
Price Before
$1.35
Price After
$1.32
Q3 FY2025+56.86%
Report Date
Aug 13, 2025
EPS Beat/Miss
+62.5%
Price Before
$0.55
Price After
$0.86
Q2 FY2025-5.30%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.30
Price After
$0.29
Q1 FY2025+0.08%
Report Date
Mar 11, 2025
EPS Beat/Miss
+18.8%
Price Before
$0.49
Price After
$0.49
Q4 FY2024-8.82%
Report Date
Nov 12, 2024
EPS Beat/Miss
-5.3%
Price Before
$1.36
Price After
$1.24
Q3 FY2024+3.96%
Report Date
Aug 13, 2024
EPS Beat/Miss
+154.6%
Price Before
$0.84
Price After
$0.88
Avg Beat Reaction+12.15%
Avg Miss Reaction-5.52%
Beat Rate6 / 8 quarters
Largest Move+56.86% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: OVID ends December
Ovid Therapeutics Inc. (OVID) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.12 (in line with the analyst consensus of $-0.12). OVID has beaten EPS estimates for 2 consecutive quarters. The next OVID earnings date is expected around September 1, 2026.
Each quarter, investors track OVID earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. OVID revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
OVID's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
OVID earnings · 4 questionsOvid Therapeutics Inc.'s next earnings report is expected around September 1, 2026. OVID typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; OVID historically reports after market close (AMC).
OVID earnings datewhen is OVID earningsOVID next earnings datewhen does OVID report earningsOVID earnings calendar
▸ Source: FMP · Ovid Therapeutics Inc. SEC filings · US GAAP · Ovid Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026